Ultrastructural changes in rat livers perfused in vitro and in vivo with a high dose of methotrexate

Histology and Histopathology

Volumn 20, Issue 4, 2005, Pages 1131-1145

  Al Ali, Saad Y ^a   Hassan, I M ^b   Sadek, S ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c ST VINCENT S HOSPITAL MANHATTAN   (United States)

Author keywords

EM; Livers; Methotrexate; Perfusion; Rat

Indexed keywords

GLYCOGEN; LIOTHYRONINE; METHOTREXATE; THYROXINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL JUNCTION; CELL MEMBRANE; CELL ORGANELLE; CELL STRUCTURE; CELL SWELLING; CELL VACUOLE; CONTROLLED STUDY; DRUG MEGADOSE; ENDOPLASMIC RETICULUM; IN VITRO STUDY; IN VIVO STUDY; ISOLATED LIVER; LIVER CELL; LIVER CELL DAMAGE; LIVER METABOLISM; LIVER PERFUSION; LIVER STRUCTURE; MALE; MAXIMUM TOLERATED DOSE; MICROVILLUS; NONHUMAN; OXYGEN CONSUMPTION; POLYSOME; RAT; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; THYROID HORMONE RELEASE; THYROXINE METABOLISM; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; FOLIC ACID ANTAGONISTS; INJECTIONS, INTRAVENOUS; LIVER; MALE; METHOTREXATE; MICROSCOPY, ELECTRON, SCANNING; OXYGEN CONSUMPTION; PERFUSION; RATS; RATS, WISTAR; THYROXINE;

ANIMALIA;

EID: 27144523215     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Abrey L., Moskowitz C., Mason W, Crump M., Stewart D., Forsyth P., Paleologos N., Correa D., Anderson N., Caron D., Zelenetz A., Nimer S. and De Angelis L. (2003). Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol. 21, 4151-4156.
2. Aithal G., Haugk B., Das S., Card T., Burt A. and Record C. (2004). Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment. Pharmacol. Therapeut. 19, 391-399.
3. Al-Ali S., Hassan I. and Al-Zuhair A. (1987). Morphological changes in the isolated rat liver perfused in a non-recirculating system. Scanning and transmission electron microscopy. Histol. Histopathol. 2, 243-250.
4. Bamias A., Aravantinos G., Deliveliotis C., Bafaloukos D., Kalofonos C., Xiros N., Zervas A., Mitropoulos D., Samantas E., Pectasides D., Papakostas P., Gika D., Kourousis C., Koutras A., Papadimitriod C., Bamias C., Kosmidis P. and Dimopoulos M. (2004). Docetaxel and cisplatin with granulocyte colony-stimulating factor (g-csf) versus mvac with g-csf in advanced urothelial carcinoma: a multicenter, randomized, phase iii study from the hellenic cooperative oncology group. J. Clin. Oncol. 22, 220-228.
5. Batchleor T., Carson K., O'Neill A., Grossman S., Alavi J. New P., Hochberg F. and Priet R. (2003). Treatment of primary CNS lymphoma with Methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. 21, 1044-1049.
6. Bathon J., Martin R., Fleischmann R., Tesser J., Schiff, M., Keystone E., Genovese M., Wasko M., Moreland L., Weaver Arthur L., Markenson J. and Finck B. (2000). A comparison of etanercept and methotrexate in patients with early arthritis. New Engl. J. Med. 343, 1586-1593.
7. Baughman P., Koehler A., Bejarano P., Lower E. and Weber F. (2003). Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch. Intern. Med. 163, 615-620.
8. Beck H. and Foged E. (1983). Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. Dermatologica 167, 94-96.
9. Bessler H., Straussberg R., Alexandrova S., Beilin B., Djaldetti M. and Hart J. (1996). Effect of oral chemotherapy on mitochondrial size of mouse intestinal cells. Cancer Chemother. Pharmacol. 38, 35-38.
10. Bjorkman D., Hammond E., Lee R., Clegg D. and Tolman K. (1988). Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheumatism 31, 1465-1472.
11. Boffa M. and Chalmers R. (1996). Methotrexate for psoriasis. Clin. Exp. Dermatol. 21, 399-408.
12. Bremnes R., Smeland E., Huseby N., Eide T. and Aarbakke J. (1991). Acute hepatotoxicity after high dose methotrexate administration to rats. Pharmacol. Toxicol. 69, 132-139.
13. Buchen S., Ngampolo D., Melton R. Hasan C., Zoubek A., Henze G., Bode U., and Fleischhack G. (2005). Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br. J. Cancer 92, 480-487.
14. Calabresi P. and Chabner B. (2001). Chemotherapy of neoplastic diseases. In: Goodman and Gilman's, The Pharmacological Basis of Therapeutics. 10th ed. Chapter 52. Hardman J.G. and Limbird L.E. (eds). McGrow-Hill. New York. pp 1389-1459.
15. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E. and Gendre J. (2005). Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54, 237-241.
16. Crawford J. (2005). Liver and billiary tract. In: Robbins and Cotran Pathologic Basis of Disease. 7th ed. Kumar V., Abbas A. and Fausto N. (eds). Elsevier Saunders. Philadelphia. pp 877-937.
17. Defamie N., Mograbi B., Roger C., Cronier L., Malassine A. and Pointis G. (2001). Distribution of gap junctional intercellular communication by lindane is associated with aberrant localization of connexin43 and zonula occludens-1 in 42GPA9 Sertoli cells. Carcinogenesis 22, 1537-1542.
18. DeSesso J. (1981). Comparative ultrastructural alterations in rabbit limb buds after teratogenic dose of either hydroxyurea or methotrexate. Teratology 23, 197-215.
19. Dixon K., Lanpher B., Chiu J., Kelley K. and Cowan K. (1994). A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J. Biol. Chem. 269, 17-20.
20. Fathi N., Mitros F., Hoffman J., Straniero N., Labreque D., Koehnke R., Furst D. (2002). Longitudinal measurements of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J. Rheumatol. 29, 2092-2098.
21. Flynn B. and Treves S. (1987). Diffuse hepatic uptake of Technicium-99m methyldiphorase in a patient receiving high dose methotrexate. J. Nucl. Med. 28, 532-534.
22. Fukuda H., Mitsumori K., Minagawa S., Kumazawa T., Tadachi K., Iinuma M., Satoh S., Satoh K., Habuchi T. and Kato T. (2005). Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy. Hinyokika Kiyo - Acta Urologica Japonica 51, 113-116.
23. Fuskevag O., Kristiansen C., Lindal S. and Aabakke J. (2000a). Maximum tolerated doses of meyhotexate and 7-hydroxymethotrexate in a model of acute toxicity in rats. Cancer Chemother. Pharmacol. 46, 69-73.
24. Fuskevag O., Kristiansen C., Olsen R., Aabakke J. and Lindal S. (2000b). Microvascular perturbation in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate. Ultrastruct. Pathol. 24, 325-332.
25. Gewirtz D., Plotkin J. and Randolph J. (1984). Interaction of probencid with methotrexate transport and release in the isolated rat hepatocyte in suspension. Cancer Res. 44, 3846-3850.
26. Ghadially F.N. (1997). Ultrastructural pathology of the cell and matrix. 4th Ed. Butterworth-Heinemann. Boston. Oxford.
27. Grossie V., Ho D. and Loo T. (1982). Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat. Cancer Treatment. Report, 66, 85-89.
28. Guan X. and Ruch R. (1996). Gap junction endocytosis and lysosomal degredation of connexin 43-P2 in WBF344 rat liver epithelial cells treated with DDT and lindane. Carcinogenesis 17, 1791-1798.
29. Hamkalo B., Farnham P., Johnston R. and Schimke R. (1985). Ultrastructural features of minute chromosomes in a methotrexate resistant mouse 3T3 cell line. Proc. Natl. Acad. Sci. USA 82, 1126-1130.
30. Hassan I., Al-Ali S. and Hassan I. (1989). Ultrastructural and hormonal metabolic studies of rat liver maintained in vitro by perfusion at 30 C and 37 C: a time course study by TEM, SEM and RIA. Histol. Histopathol. 4, 411-419.
31. Hassan I., Al-Ali S. Hassan M., Sadek S. and Clavel M. (1990). The effect of hypothermia on metabolism and oxygen consumption in the isolated perfused rat liver. Medical Principles Practice 2, 47-53.
32. Hayashi T., Matesic D., Nomata K., Kang K., Chang C. and Trosko J. (1997). Stimulation of cell proliferation and inhibition of gap junctional intercellular communication by linoleic acid. Cancer Lett. 112, 103-111.
33. Hendel J., Poulsen H., Nyfors B. and Nyfors A. (1985). Changes in liver histology during methotrexate therapy of psoriasis correlated to concentration of methotrexate and folate in erythrocytes. Acta Pharmacol. Toxicol. 56, 321-326.
34. Hinton R. and Grasso P. (1999). Hepatotoxicity. In: General and applied toxicology. 2nd ed. Vol. 2. Chapter 42. Ballantyne B., Marrs T. and Syversen T. (eds). McMillan Reference. London. pp 853-891.
35. Hoekstra M., Haagsma C., Doelman C. and van de Laar M. (2005). Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann. Rheumat. Dis. 64, 141-143.
36. Hu W., Jones P., Upham B., Trosko J., Lau C. and Giesy J. (2002). Inhibition of gap junctional intercellular communication by perfluorinated compounds in rat liver and dolphin kidney epithelial cell lines in vitro and Sprague-Dawely rats in vivo. Toxicol. Sci. 68, 429-436.
37. Kamen B., Moulder J., Kun L., Ring B., Adams S., Fish B., and Holcenberg J. (1984). Effects of single dose and fractionated cranial irradiation on rat brain. Accumulation of methotrexate. Cancer Res. 44, 5092-5094.
38. Kaplan M., Cheng S., Price L. and Bonis P. (2004). A Randomized Controlled Trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten-year results. Hepatology 39, 915-923.
39. Kremer J. and Kaye G. (1989). Electron microscopic analysis of sequential liver biopsy samples from patients with rheumatoid arthritis. Correlation with light microscopic findings. Arthrit. Rheumat. 32, 1202-1213.
40. Kremer J., Kaye G., Kaye N., Ishak K. and Axiotis C. (1995). Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Flowing over long treatment intervals and correlation with clinical and laboratory variables. Arthrit. Rheum. 38, 1194-1203.
41. Kumar V., Abbas A. and Fausto N. (2005). Fobbins and Cotran Pathologic Basis of Disease. 7th ed. Elsevier Saunders. Philadelphia. pp 3-46.
42. Laine L. and Chojkier M. (1986). Hepatic collagen production in the rat is unaffected by methotrexate. Proc. Soc. Exp. Biol. Med. 182, 194-200.
43. Lawrence C., Strange R., Summerly R., Scriven A., Elmahallawy M., Wood A., Fletcher P. and Beckett G. (1983). Assessment of liver function using fasting bile salt concentration in psoriasis prior to and during methotrexate therapy. Clin. Chem. Acta 129, 341-351.
44. Lemberg A., Daunas J., Brodoff B., Penhos J., Sodero E. and White R. (1967). Action of methotrexate on metabolism of lipids and carbohydrates of the perfused isolated liver. Cancer 20, 1668-1672.
45. Leszczynska-Bisswanger A. and Pfaff E. (1985a). Effect of depletion of cellular glutathione on methotrexate influx, efflux and retention in hepatocytes. Biochem. Pharmacol. 34, 1627-1634.
46. Leszczynska-Bisswanger A. and Pfaff E. (1985b). Diurnal variation of methotrexate transport and accumulation in hepatocytes. A consequence of variations in cellular glutathione. Biochem. Pharmacol. 34, 1635-1638.
47. Luyckx M., Cazin J., Brunet C., Gosselin P. and Demaille M. (1985). Clinical pharmacokinetics of 6-hour infusion of high dose methotrexate. Preliminary trial of monitoring high infusion doses. Eur. Clin. Pharmacol. 28, 457-462.
48. Maia M., Saivin S., Chatelut E., Malmary M. and Houin G. (1996). In vitro and in vivo protein binding of methotrexate assessed by microdialysis. Internatl. J. Clin. Pharmacol. Therapeut. 34, 335-341.
49. Maiti S. and Chen G. (2003). Methotrexate is a novel inducer of rat liver and intestinal sulfotransferases. Arch. Biochem. Biophys. 418, 161-168.
50. Matsui H., Suzuka K., Yamazawa K., Tanaka N., Mitsuhashi A., Seki K. and Sekiya S. (2005). Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol. Oncol. 96, 616-620.
51. Merker G., Helling M., Krahl M. and Aigner K. (1983). Ultrastructural changes in dog liver cell after isolated liver perfusion with various cytotoxins. Recent Results Cancer Res. 86, 103-109.
52. Meyers P., Schwartz C., Krailo M., Kleinerman E., Betcher D., Bernstein M., Conrad E., Ferguson W., Gebhardt M., Goorin A., Harris M., Healey J., Huvos A., Link M. Montebello J., Nadel H., Nieder M., Sato J., Siegal G., Weiner M., Wells R., Wold L., Womer R. and Grier H. (2005). Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 23, 2004-2011.
53. Miller L. (1973). Technique of isolated rat liver perfusion. Bartosek I., Guaitani A. and Miller L. (eds). Raven Press. New York. pp 11-52.
54. Myagkaya G., van Veen H. and James K. (1985). Quantitative analysis of mitochondrial flocculent densities in rat hepatocytes during normothermic and hypothermic ischaemia in vitro. Virchow Arch. (B) 49, 61-66.
55. Nayak N. (1981). Bridging necrosis of the liver. Tropical Gastroenterol. 2, 1-3.
56. Nyfors A. and Hopwood D. (1977). Liver ultrastructure in psoriatics related methotrexate therapy. 1. A prospective study of findings in hepatocytes from 24 patients before and after methotrexate treatment. Acta Pathol. Microbiol. Scand. 85, 787-800.
57. Phillips M., Poucell S., Patterson J. and Valencia P. (1987). The liver: An atlas and text of ultrastructural pathology. Raven Press. New York. pp 159-238.
58. Poortmans P., Kluin-Nelemans H., Haaxma-Reiche H., Veer M., Hansen M., Soubeyran P., Taphoorn M., Thomas J., van den Bent M., Fickers M., van Imhoff G. Rozewicz C., Teodorovic I. and van Glabbeke M. (2003). High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-aids-related primary central nervous system lymphoma: European organization for research and treatment of cancer lymphoma group phase II trial 20962. J. Clin. Oncol. 21, 4483-4488.
59. Rigacci L., Carrai V., Nassi L., Alterini R., Longo G., Bernardi F. and Bosi A. (2005). Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study. Cancer 103, 970-977.
60. Ros S., Juanola X., Condom E., Canas C., Riera J., Guardiola J., Del Blanco J., Rebasa, P., Valverde J. and Roig-Escofet D. (2002). Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Scand. J. Rheumatol. 31, 330-336.
61. Ross B. (1972). Perfusion techniques in biochemistry: a laboratory manual in the use of perfused organs in biochemical experimentation. Oxford University Press. London. pp 135-220.
62. Sai K., Kang K., Hirose A., Hasegwa R., Trosko J. and Inoue T. (2001). Inhibition of apoptosis by pentachlorophenol in v-myc-transfected rat liver epithelial cells: relation to down-regulation of gap junctional intercellular communication. Cancer Lett. 173, 163-174.
63. Scheffel U., Wagner H. and Tsan M. (1986). Enhancement of hepatic Gallium-67 uptake by sialo-transferrin. J. Nucl. Med. 27, 395-398.
64. Scheufler E. (1982). Evidence for nonlinear pharmacokinetics of methotrexate in the rat. Pharmacology 25, 51-56.
65. Scheufler E., Zetler G. and Iven H. (1981). Pharmacokinetics and organ distribution of methotrexate in the rat. Pharmacology 23, 75-81.
66. Schmiegelow K., Björk O., Glomstein A., Gustafsson G., Keiding N., Kristinsson J., Makipernaa A., Rosthj S., Szumlanski C., Sorensen T. and Weinshilboum R. (2003). Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J. Clin. Oncol. 21, 1332-1339.
67. Scott D. (2005). Etanercept in arthritis (Review). Int. J. Clin. Pract. 59, 114-118.
68. Smeland E., Bremnes R., Andersen A., Jaeger R., Eide T., Huseby N. and Aarbakke J. (1994). Renal and hepatic toxicity after high dose 7-hydroxymethotrexate in the rat. Cancer Chemother. Pharmacol. 34, 119-124.
69. Tada M., Inui K., Koike T. and Takaoka K. (2005). Use of local electroporation enhances methotrexate effects with minimum dose in adjuvant-induced arthritis. Arth. Rheumatis. Rheumatism. 52, 637-641.
70. Velazquez J., Frantseva M. and Naus C. (2003). Gap junctions and neuronal injury: protectants or executioners? Neuroscientist 9, 5-9.
71. Weiland D., Mondon C. and Reaven G. (1979). Prolongation of insulin removal by perfused liver from spontaneously obes rat. Diabetologia 16, 173-177.
72. Weiss R., Woolf S., Demakos E., Holland E, Berry D., Falson G., Cirrincione T., Robbins A., Bothun S., Henderson I. and Norton L. (2003). Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the cancer and leukemia group b. J. Clin. Oncol. 21, 1825-1835.
73. Wyatt E., Sutter S. and Drake L. (2001). Dermatological pharmacology. In: Goodman and Gilman's, the pharmacological basis of therapeutics. 10th ed. Chapter 65. Hardman J.G. and Limbird L.E. (eds). McGrow-Hill. New York. pp 1795-1818.
74. Zimmerman H. and Ishak K. (1995). Hepatic injuries due to drugs and toxins. In: Pathology of liver. 3rd ed. MacSween R.N., Anthony P.P., Scheur P.J., Burt A.D. and Portmann B.C. (eds) Churchill Livingstone. Edinburgh. pp 563-633.